Moderna plots lung cancer trial for Merck-partnered vax, piggybacking on Keytruda's recent win

Moderna's buzzy cancer vaccine partnership with Merck will soon take a leap into lung cancer, after recent clinical data showed the shot—alongside Merck's blockbuster Keytruda—significantly reduced risk of recurrence or death in patients with melanoma.